Search

Your search keyword '"Avni-Biron, Irit"' showing total 162 results

Search Constraints

Start Over You searched for: Author "Avni-Biron, Irit" Remove constraint Author: "Avni-Biron, Irit"
162 results on '"Avni-Biron, Irit"'

Search Results

1. Environmental Factors Associated With Risk of Crohn’s Disease Development in the Crohn’s and Colitis Canada - Genetic, Environmental, Microbial Project

3. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα

4. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

5. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study

6. Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel

7. The Role of Small-Bowel Capsule Endoscopy in the Diagnostic Algorithm of Complicated Perianal Disease.

10. Discordant effects of ex-vivo JAK inhibition on inflammatory responses in colonic compared to ileal mucosa

11. Early Indolent Course of Crohn’s Disease in Newly Diagnosed Patients Is Not Rare and Possibly Predictable

12. Tofacitinib is an effective treatment for moderate to severe ulcerative colitis, and intestinal ultrasound can discriminate response from non-response: a pragmatic prospective real-world study.

13. Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases [IBD]: Real World Results from the International Organization for the study of IBD

14. A Real-World Prospective Cohort Study of Patients With Newly Diagnosed Crohn’s Disease Treated by a Multidisciplinary Team: 1-Year Outcomes

17. Serologic Response and Safety after a Third Dose of the COVID-19 BNT162b2 Vaccine in Patients with Inflammatory Bowel Diseases

24. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease—A Multicenter Retrospective European Study

25. Multidisciplinary Perinatal Care in IBD

27. SARS-CoV-2 IgG Antibody Levels in Women with IBD Vaccinated during Pregnancy

29. Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort study

31. Immune function in newborns with in-utero exposure to anti-TNFα therapy

32. Endoscopic Postoperative Recurrence in Crohn’s Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study

34. Sa1630: PATIENT AND PHYSICIAN PERSPECTIVE ON DISEASE CONTROL 1-YEAR AFTER DIAGNOSIS OF CROHN'S DISEASE: RESULTS FROM REAL-WORLD PROSPECTIVE INCEPTION COHORT

35. Su1564: USTEKINUMAB DURING PREGNANCY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE MULTICENTER COHORT STUDY

36. Su1488: WITHIN 6 MONTHS FROM COVID-19 BNT162B2 VACCINE PATIENTS WITH INFLAMMATORY BOWEL DISEASES TREATED WITH ANTI-TNFα HAVE SIGNIFICANTLY LOWER SEROLOGIC RESPONSES

37. Sa1601: FIRST YEAR REMISSION RATES AMONG PATIENTS WITH NEWLY DIAGNOSED CROHN'S DISEASE: DATA FROM A REAL-WORLD PROSPECTIVE INCEPTION COHORT

38. Mo1557: DRUG PERSISTENCE AND ENDOSCOPIC, HISTOLOGIC AND BIOCHEMICAL REMISSION RATES AMONG PATIENTS FOLLOWING ILEAL-ANAL POUCH ANASTOMOSIS TREATED WITH BIOLOGIC THERAPY: RESULTS FROM A PROSPECTIVE PATIENT COHORT

41. 27 DEVELOPMENT AND VALIDATION OF AN INTEGRATED RISK SCORE FOR PREDICTING FUTURE RISK OF CROHN'S DISEASE UP TO 7 YEARS BEFORE DIAGNOSIS IN HEALTHY FIRST-DEGREE RELATIVES: THE CCCGEM PROJECT, A MULTICENTRE PROSPECTIVE COHORT STUDY

42. Su1813 EXTERNALLY VALIDATED ARTIFICIAL INTELLIGENCE EXPLAINABLE INTERACTIVE TOOL FOR PREDICTING AND COMPARING THE DRUG SUSTAINABILITY OF INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ACTIVE ULCERATIVE COLITIS

43. Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease—the Israeli Real-World Experience

44. Video Capsule Endoscopy after Bariatric Surgery: A Tertiary Referral Center Experience.

46. COVID-19 in Patients with Inflammatory Bowel Disease: The Israeli Experience

47. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

48. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study

49. An Inception Cohort of Patients with Newly Diagnosed Crohn's Disease: Therapeutic Targets Achieved One Year after Diagnosis

50. Decreased Immune Response to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases Treated with Anti TNFα

Catalog

Books, media, physical & digital resources